Cox proportional hazard model univariable analysis for OS and EFS in all patients
| . | OS, HR (95% CI) . | EFS, HR (95% CI) . |
|---|---|---|
| Age | 0.99 (0.96-1.02) | 0.98 (0.96-1.00) |
| AML (other vs de novo) | 3.58 (1.20-10.7) | 1.87 (0.8-4.39) |
| DNMT3A mutated vs wild type | 0.79 (0.45-1.37) | 0.95 (0.7-1.29) |
| FLT3-ITD mutated vs wild type | 2.50 (1.06-5.86) | 1.87 (1.06-3.28) |
| N/KRAS mutations vs wild type | 1.23 (0.28-5.38) | 0.59 (0.18-1.90) |
| IDH1/2 mutations vs wild type | 1 (0.41-2.42) | 1.33 (0.76-2.33) |
| Molecular progression vs molecular persistence | 1.54 (0.38-1.75) | 0.71 (0.27-1.89) |
| Molecular relapse vs molecular persistence | 2.09 (0.79-5.58) | 1.13 (0.63-2.01) |
| More than 365 NPM1 copies /105 ABL at relapse (vs ≤365 copies) | 1.51 (0.64-3.53) | 1.01 (0.59-1.72) |
| Venetoclax combination (LDAC vs AZA) | 0.87 (0.38-6.16) | 0.86 (0.50-1.49) |
| Allogeneic HSCT after treatment vs no HSCT | 1.28 (0.52-3.16) | 0.81 (0.43-1.56) |
| . | OS, HR (95% CI) . | EFS, HR (95% CI) . |
|---|---|---|
| Age | 0.99 (0.96-1.02) | 0.98 (0.96-1.00) |
| AML (other vs de novo) | 3.58 (1.20-10.7) | 1.87 (0.8-4.39) |
| DNMT3A mutated vs wild type | 0.79 (0.45-1.37) | 0.95 (0.7-1.29) |
| FLT3-ITD mutated vs wild type | 2.50 (1.06-5.86) | 1.87 (1.06-3.28) |
| N/KRAS mutations vs wild type | 1.23 (0.28-5.38) | 0.59 (0.18-1.90) |
| IDH1/2 mutations vs wild type | 1 (0.41-2.42) | 1.33 (0.76-2.33) |
| Molecular progression vs molecular persistence | 1.54 (0.38-1.75) | 0.71 (0.27-1.89) |
| Molecular relapse vs molecular persistence | 2.09 (0.79-5.58) | 1.13 (0.63-2.01) |
| More than 365 NPM1 copies /105 ABL at relapse (vs ≤365 copies) | 1.51 (0.64-3.53) | 1.01 (0.59-1.72) |
| Venetoclax combination (LDAC vs AZA) | 0.87 (0.38-6.16) | 0.86 (0.50-1.49) |
| Allogeneic HSCT after treatment vs no HSCT | 1.28 (0.52-3.16) | 0.81 (0.43-1.56) |
AZA, azacitidine.